
Share
As prescription costs rise and demand for coordinated healthcare services grows, Humana's latest investment in Florida aims to enhance its prescription delivery infrastructure.
Humana’s CenterWell Pharmacy has announced a significant $83 million investment in a new pharmacy distribution center in Orlando, Florida. The facility, which spans 162,000 square feet, is designed to bolster the company's prescription delivery capabilities and offer an improved experience for members and patients.
The new distribution center can process up to 64,000 prescriptions daily and will employ 165 people, according to Humana. The facility will not only serve Humana members but also provide payer-agnostic services such as direct-to-consumer and direct-to-employer partnerships. These services are becoming increasingly popular as prescription costs continue to rise.
Bethanie Stein, president of pharmacy at Humana, emphasized the strategic importance of this investment: “This new CenterWell Pharmacy reflects both our excitement for growth and our deep commitment to delivering better outcomes for patients. As demand continues to grow, we are expanding our capacity with modern, high-performing pharmacies like Orlando, ensuring more people can access their medications safely, reliably, and in a way that supports long-term adherence and health.”
Humana has a significant presence in Florida, serving as the largest Medicare Advantage carrier in the state with 1.1 million members. The company also manages Medicaid plans for 540,000 Floridians and provides TRICARE to over 770,000 individuals. Humana operates 200 primary care locations under CenterWell, Conviva, and MaxHealth brands, as well as 50 CenterWell and Trilogy Home Health facilities in the state.
Sanjay Shetty, M.D., president of CenterWell, highlighted the broader impact of this expansion: “As Florida’s senior population continues to grow, CenterWell’s integrated care model offers improved health and simplified care for those we serve. This critical expansion of pharmacy services deepens our commitment to our patients in Florida and to the entire community, including thousands of local teammates.”

The new distribution center is part of Humana's broader strategy to enhance its healthcare infrastructure and support career training programs through CenterWell Pharmacy. These initiatives are crucial as the state’s senior population grows, driving increased demand for comprehensive and coordinated care services.
Humana’s significant investment in Florida underscores the company's commitment to expanding its footprint in a key market. The $83 million allocation not only strengthens Humana's prescription delivery capabilities but also positions the company to capitalize on growing trends in direct-to-consumer and employer partnerships.
The facility’s capacity to process 64,000 prescriptions daily highlights Humana’s focus on efficiency and scalability. This is particularly important as healthcare payers face increasing scrutiny over their use of technology and data management practices. For instance, Massachusetts Attorney General Campbell has sued UnitedHealthcare for allegedly defrauding the state, and lawmakers have shown interest in overseeing payers' use of AI, which could impact future investments and operational strategies.
In the context of these challenges, Humana’s investment in modern infrastructure demonstrates a proactive approach to meeting regulatory expectations while enhancing patient care. As the healthcare landscape continues to evolve, such strategic investments will be crucial for maintaining competitive advantage and ensuring long-term sustainability.
The new distribution center is expected to play a vital role in supporting Humana's broader mission of delivering high-quality, accessible healthcare services to its growing member base in Florida.
Tags
Original Sources
Humana invests $83M in new Florida pharmacy distribution center
↗ https://www.fiercehealthcare.com/payers/humana-invests-83m-new-florida-pharmacy-distribution-center
About the author
Marcus began tracking AI's market implications in 2016, noticing AI-related patent filings accelerating ahead of earnings upgrades before most of the sell-side had caught on. A former fixed-income quantitative analyst, he spent two decades building models that priced risk across emerging markets before pivoting to cover the economic impact of AI full-time. His writing translates opaque technical developments into clear risk/reward terms — and he's rarely diplomatic about the gap between AI valuations and underlying fundamentals. He believes most market participants still underestimate AI's long-run deflationary effect on knowledge work.
More from The Analyst →This Week's Edition
3 June 2026
133 articles
Related Articles
Related Articles
More Stories